Latest Breaking News On - Eclared navb us63937x2027 - Page 1 : comparemela.com

Navidea Biopharmaceuticals, Inc. , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors declared a dividend. | June 16, 2023

United statesNavidea manoceptNavidea biopharmaceuticals incSecurities exchangeCompany board of directorsCorporation lawExchange commissionNavidea biopharmaceuticalsSeriesk preferred stockDelaware general corporationSecurities actSecurities exchange actAnnual reportNc stock exchangePress releaseEclared navb us63937x2027